-
-
Login
A global survey by Roche of more than 4,300 people with diabetes has highlighted the daily planning, uncertainty and mental effort involved in managing the condition.
News from Portal Diabetes that new medtech for an implantable insulin pump has reached an early regulatory milestone in the US.
After gaining a CE mark in January, the rollout of Eversense 365 implantable sensor, designed to last for a full year is expected in 2026.
Medtronic officially spins off diabetes business to become standalone company MiniMed. Includes news of regulatory updates for the MiniMed insulin pump system.
An update on Dexcom's 2026 plans with changes in senior leadership and a push for wider access to CGM technology.
Reporting on the latest from Beta Bionics following FDA warning letter and insider share sales.
Medtronic has announced 3 milestones that broaden MiniMed 780G hybrid-closed loop system in the USA. The news covers Medicare access, new insulin options, and an expansion to people with insulin-requiring type 2 diabetes.
Medtronic has received FDA clearance for a new mobile app called MiniMed Go, designed to connect its smart insulin pens with the Instinct sensor by Abbott.
Abbott receives warning letter for FreeStyle Libre sensors from the FDA following an inspection. The letter focuses on problems with Abbott's tests and verification of accuracy of their CGMs.
Details of Insulet's long-term vision and new details about Omnipod 6, alongside upgrades to existing systems and a fully closed-loop option for people with type 2 diabetes.
A recent update to the Libre 3 app in the US now enables users to snap their meal to learn how their glucose will change. At the same time the app has made it possible to see levels on a smartwatch.
What longer-wear monitoring, fewer sensor changes and tighter integration could mean for future CGM and pump choices.
